VTVTNasdaqPharmaceutical PreparationsFiscal year ends December 31
vTv Therapeutics Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$26.94+0.40 (+1.51%)
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
40.6%
2M of 4M shares
Institutional holders
45
17 new, 6 sold out
Net institutional buying
0M
In Q2 2026
Insider trades, 12 months
0 buys · 0 sales
Open-market trades only
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Srinivas Akkaraju | 403,942 | 9.90% | 13D (active) amendment | Dec 8, 2025 |
| Raymond Debbane | 393,098 | 9.40% | 13G (passive) amendment | Sep 30, 2025 |
| Israel A. Englander | 342,481 | 8.70% | 13G (passive) amendment | Sep 30, 2026 |
| Ortav Yehudai | 340,536 | 9.90% | 13G (passive) | Aug 29, 2025 |
| Millennium Management LLC | 225,073 | 5.70% | 13G (passive) amendment | Apr 13, 2026 |
| Millennium Group Management LLC | 198,237 | 5.00% | 13G (passive) | Mar 24, 2026 |
| Abigail P. Johnson | 178,200 | 7.32% | 13G (passive) | Nov 12, 2024 |
| The ROP Revocable Trust dated 1/9/2018 | 1,535,685 | 50.30% | 13D (active) amendment | Feb 27, 2024 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of VTVT | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Samsara BioCapital, LLC | 298,496 | 7.55% | $11.24M | – | 0.92% |
| Millennium Management LLC | 269,874 | 6.83% | $10.16M | +63,586 | 0.00% |
| FMR LLC | 260,391 | 6.59% | $9.80M | – | 0.00% |
| Siren, L.L.C. | 163,000 | 4.12% | $6.14M | – | 0.12% |
| Baker Bros. Advisors LP | 148,314 | 3.75% | $5.58M | – | 0.03% |
| Vanguard Capital Management LLC | 94,463 | 2.39% | $3.56M | −14,459 | 0.00% |
| Trails Edge Capital Partners, LP | 85,192 | 2.15% | $3.21M | −54,386 | 0.51% |
| Aisling Capital Management LP | 50,000 | 1.26% | $1.88M | New | 0.40% |
| Marshall Wace, Llp | 39,560 | 1.00% | $1.49M | +26,171 | 0.00% |
| Geode Capital Management, LLC | 32,470 | 0.82% | $1.22M | −416 | 0.00% |
| Renaissance Technologies LLC | 17,454 | 0.44% | $657.14K | New | 0.00% |
| Vanguard Fiduciary Trust Co | 16,239 | 0.41% | $611.40K | +113 | 0.00% |
| BlackRock, Inc. | 14,731 | 0.37% | $554.62K | +2,129 | 0.00% |
| Jane Street Group, LLC | 13,703 | 0.35% | $515.92K | New | 0.00% |
| State Street Corp | 12,266 | 0.31% | $461.82K | +1,600 | 0.00% |
| Two Sigma Investments, LP | 11,486 | 0.29% | $432.45K | New | 0.00% |
| Verdad Advisers, LP | 8,996 | 0.23% | $338.70K | New | 0.32% |
| Integrated Quantitative Investments LLC | 8,210 | 0.21% | $309.11K | New | 0.05% |
| Susquehanna International Group, Llp | 8,023 | 0.20% | $302.07K | New | 0.00% |
| Quadrature Capital Ltd | 6,305 | 0.16% | $237.38K | New | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 45 | 2M | 40.6% | 17 / 6 | 8 / 6 | 0M | 0M |
| Q1 2026 | 35 | 1M | 37.6% | 12 / 7 | 4 / 3 | 0M | 0M |
| Q4 2025 | 27 | 1M | 32.5% | 7 / 8 | 3 / 3 | 0M | 0M |
| Q3 2025 | 23 | 1M | 25.0% | 3 / 8 | 3 / 1 | 0M | 0M |
| Q2 2025 | 21 | 1M | 14.8% | 3 / 6 | 3 / 3 | 0M | 0M |
| Q1 2025 | 21 | 1M | 14.5% | 5 / 2 | 6 / 1 | 0M | 0M |
| Q4 2024 | 17 | 1M | 13.9% | 1 / 5 | 1 / 3 | 0M | 0M |
| Q3 2024 | 20 | 1M | 13.7% | 6 / 2 | 1 / 4 | 0M | 0M |
| Q2 2024 | 19 | 0M | 8.8% | 5 / 3 | 2 / 5 | 0M | 0M |
| Q1 2024 | 19 | 0M | 8.5% | 6 / 6 | 4 / 1 | 0M | 0M |
| Q4 2023 | 14 | 0M | 1.8% | 13 / 0 | 1 / 0 | 0M | 0M |
| Q3 2023 | 1 | 0M | 0.0% | 1 / 0 | 0 / 0 | 0M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of VTVT | Value | % of fund | As of |
|---|---|---|---|---|---|
| Select Biotechnology Portfolio | 260,391 | 6.59% | $8.68M | 0.16% | May 31, 2026 |
| Vanguard Total Stock Market Index Fund | 60,763 | 1.54% | $2.29M | 0.00% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 31,402 | 0.79% | $1.18M | 0.00% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 14,732 | 0.37% | $491.31K | 0.00% | May 31, 2026 |
| iShares Micro-Cap ETF | 7,234 | 0.18% | $272.36K | 0.02% | Jun 30, 2026 |
| Fidelity Total Market Index Fund | 4,779 | 0.12% | $159.38K | 0.00% | May 31, 2026 |
| Fidelity Series Total Market Index Fund | 4,193 | 0.11% | $139.84K | 0.00% | May 31, 2026 |
| Fidelity Nasdaq Composite Index Fund | 2,524 | 0.06% | $84.18K | 0.00% | May 31, 2026 |
| Vanguard Institutional Total Stock Market Index Fund | 1,523 | 0.04% | $57.34K | 0.00% | Jun 30, 2026 |
| Vanguard Balanced Index Fund | 775 | 0.02% | $29.18K | 0.00% | Jun 30, 2026 |
| 1290 VT Micro Cap Portfolio | 486 | 0.01% | $18.30K | 0.01% | Jun 30, 2026 |
| Victory Extended Market Index Fund | 236 | 0.01% | $7.63K | 0.00% | Jul 31, 2026 |
| Total Stock Market Index Trust | 88 | 0.00% | $3.31K | 0.00% | Jun 30, 2026 |
| Knights of Columbus U.S. ALL CAP INDEX FUND | 11 | 0.00% | $356 | 0.00% | Jul 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Paul J. Sekhri | Pres, CEO and Exec Chairperson, Director | 392,212 | 9.92% | Feb 18, 2026 |
| Michael Stephen Tung | EVP & CFO | – | – | Feb 18, 2026 |
| Barry K. Brown | Chief Accounting Officer | 4 | 0.00% | Apr 11, 2025 |
| Felix Baker | Director | – | – | Jun 29, 2026 |
| Brothers Life Sciences LP Baker | Director | – | – | Jun 29, 2026 |
| Bros. Advisors (GP) LLC Baker | Director | – | – | Jun 29, 2026 |
| 667, L.P. | Director | 89,254 | 2.26% | Jun 29, 2026 |
| Daniel K. Spiegelman | Director | – | – | Jun 29, 2026 |
| Fahed Al-Marzooqi | Director | – | – | Jun 29, 2026 |
| Srinivas Akkaraju | Director | 312,784 | 7.91% | Jun 29, 2026 |
| Bros. Advisors Lp Baker | Director | 142,135 | 3.59% | Jun 29, 2026 |
| Julian Baker | Director | 12,368 | 0.31% | Jun 29, 2026 |
| Anne M. Phillips | Director | – | – | Jun 29, 2026 |
| Samsara BioCapital, L.P. | 10% owner | 206,784 | 5.23% | Dec 6, 2024 |
| Samsara BioCapital GP, LLC | 10% owner | – | – | Dec 6, 2024 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Srinivas Akkaraju Director | Sep 22, 2025 | Award | +106,000 | $15.27 | $1.62M | 106,000 |
| Julian Baker Director | Sep 3, 2025 | Award | +4,308 | – | – | 12,368 |
| Julian Baker Director | Sep 3, 2025 | Award | +46,692 | – | – | 135,946 |
| Paul J. Sekhri Pres, CEO and Exec Chairperson, Director | Nov 18, 2024 | Buy | +1,844 | $16.96 | $31.27K | 5,000 |
| Paul J. Sekhri Pres, CEO and Exec Chairperson, Director | Nov 15, 2024 | Buy | +1,378 | $16.35 | $22.53K | 1,378 |
| Paul J. Sekhri Pres, CEO and Exec Chairperson, Director | Nov 15, 2024 | Buy | +1,778 | $16.88 | $30.01K | 3,156 |
| Samsara BioCapital, L.P. 10% owner | Mar 5, 2024 | Other | −58,836 | – | – | 206,784 |
| Srinivas Akkaraju Director, 10% owner | Mar 5, 2024 | Returned to company | −58,836 | – | – | 206,784 |
| 667, L.P. Director | Mar 5, 2024 | Returned to company | −52,881 | – | – | 89,254 |
| 667, L.P. Director | Mar 5, 2024 | Returned to company | −4,776 | – | – | 8,060 |
| Srinivas Akkaraju Director, 10% owner | Feb 27, 2024 | Award | +224,732 | $11.81 | $2.65M | 265,620 |
| John A. Fry Director | Nov 29, 2022 | Buy | +40,461 | $0.83 | $33.58K | 61,000 |
| John A. Fry Director | Nov 28, 2022 | Buy | +20,539 | $0.83 | $17.05K | 20,539 |
| Ronald O. Perelman 10% owner | Dec 20, 2021 | Sale | −87,000 | $1.15 | $100.05K | 36,519,212 |
| Hersh Kozlov Director | Feb 26, 2021 | Buy | +10,000 | $2.74 | $27.40K | 25,000 |
| Rich S. Nelson Director | Feb 26, 2021 | Buy | +10,000 | $2.86 | $28.60K | 10,000 |
| Rich S. Nelson Director | Feb 26, 2021 | Buy | +50,000 | $2.86 | $143.00K | 50,000 |
| Ronald O. Perelman 10% owner | Dec 17, 2020 | Buy | +625,000 | $1.60 | $1.00M | 36,606,212 |
| Ronald O. Perelman 10% owner | Dec 10, 2020 | Buy | +625,000 | $1.60 | $1.00M | 35,981,212 |
| Ronald O. Perelman 10% owner | Nov 24, 2020 | Buy | +625,000 | $1.60 | $1.00M | 35,356,212 |
| Hersh Kozlov Director | May 15, 2020 | Buy | +10,000 | $3.00 | $30.00K | 15,000 |
| Ronald O. Perelman 10% owner | May 12, 2020 | Buy | +625,000 | $1.60 | $1.00M | 34,731,212 |
| Jeffrey B. Kindler Director | Mar 10, 2020 | Option exercise | +11,667 | – | – | 35,000 |
| Ronald O. Perelman 10% owner | Feb 25, 2020 | Buy | +1,250,000 | $1.60 | $2.00M | 34,106,212 |
| Ronald O. Perelman 10% owner | Jan 28, 2020 | Buy | +1,250,000 | $1.60 | $2.00M | 32,856,212 |
| Ronald O. Perelman 10% owner | Jan 7, 2020 | Buy | +1,250,000 | $1.60 | $2.00M | 31,606,212 |
| Ronald O. Perelman 10% owner | Dec 18, 2019 | Buy | +1,369,863 | $1.46 | $2.00M | 30,356,212 |
| Ronald O. Perelman 10% owner | Nov 26, 2019 | Buy | +1,369,863 | $1.46 | $2.00M | 28,986,349 |
| Ronald O. Perelman 10% owner | Nov 12, 2019 | Buy | +1,369,863 | $1.46 | $2.00M | 27,616,486 |
| Ronald O. Perelman 10% owner | Oct 24, 2019 | Buy | +1,369,863 | $1.46 | $2.00M | 26,246,623 |
| Ronald O. Perelman 10% owner | Sep 27, 2019 | Buy | +1,369,863 | $1.46 | $2.00M | 24,876,760 |
| Ronald O. Perelman 10% owner | Sep 18, 2019 | Buy | +606,061 | $1.65 | $1.00M | 23,506,897 |
| Hersh Kozlov Director | Sep 13, 2019 | Buy | +5,000 | $1.65 | $8.25K | 5,000 |
| Ronald O. Perelman 10% owner | Sep 11, 2019 | Buy | +606,061 | $1.65 | $1.00M | 22,900,836 |
| Ronald O. Perelman 10% owner | Sep 4, 2019 | Buy | +606,061 | $1.65 | $1.00M | 22,294,775 |
| Ronald O. Perelman 10% owner | Aug 22, 2019 | Buy | +50,000 | $1.38 | $69.00K | 21,688,714 |
| Ronald O. Perelman 10% owner | Aug 19, 2019 | Buy | +150,000 | $1.31 | $196.50K | 21,638,714 |
| Ronald O. Perelman 10% owner | Aug 6, 2019 | Buy | +1,212,121 | $1.65 | $2.00M | 21,488,714 |
| Ronald O. Perelman 10% owner | Jul 9, 2019 | Buy | +1,212,121 | $1.65 | $2.00M | 20,276,593 |
| Ronald O. Perelman 10% owner | Jun 25, 2019 | Buy | +1,212,121 | $1.65 | $2.00M | 19,064,472 |
| Ronald O. Perelman 10% owner | May 15, 2019 | Buy | +1,358,698 | $1.84 | $2.50M | 17,852,351 |
| Jeffrey B. Kindler Executive Chairman, Director | Mar 10, 2019 | Option exercise | +11,666 | – | – | 23,333 |
| Ronald O. Perelman 10% owner | Feb 28, 2019 | Buy | +815,217 | $1.84 | $1.50M | 16,493,653 |
| Ronald O. Perelman 10% owner | Feb 14, 2019 | Buy | +815,217 | $1.84 | $1.50M | 15,678,436 |
| Ronald O. Perelman 10% owner | Jan 29, 2019 | Buy | +815,217 | $1.84 | $1.50M | 14,863,219 |
| Ronald O. Perelman 10% owner | Jan 16, 2019 | Buy | +815,217 | $1.84 | $1.50M | 14,048,002 |
| Ronald O. Perelman 10% owner | Dec 27, 2018 | Buy | +815,217 | $1.84 | $1.50M | 13,232,785 |
| Ronald O. Perelman 10% owner | Nov 29, 2018 | Buy | +1,879,700 | $1.33 | $2.50M | 12,417,568 |
| Ronald O. Perelman 10% owner | Nov 6, 2018 | Buy | +1,879,699 | $1.33 | $2.50M | 10,537,868 |
| Ronald O. Perelman 10% owner | Sep 27, 2018 | Buy | +1,879,699 | $1.33 | $2.50M | 8,658,169 |
| Ronald O. Perelman 10% owner | Sep 6, 2018 | Buy | +1,879,699 | $1.33 | $2.50M | 6,778,470 |
| Paul G. Savas Director | Sep 6, 2018 | Buy | +5,000 | $1.00 | $5.00K | 91,781 |
| Ronald O. Perelman 10% owner | Aug 10, 2018 | Buy | +570,777 | $4.38 | $2.50M | 4,898,771 |
| Ronald O. Perelman 10% owner | Jul 6, 2018 | Buy | +570,776 | $4.38 | $2.50M | 4,327,994 |
| Ronald O. Perelman 10% owner | Jun 18, 2018 | Buy | +570,776 | $4.38 | $2.50M | 3,757,218 |
| Ronald O. Perelman 10% owner | May 24, 2018 | Buy | +570,776 | $4.38 | $2.50M | 3,186,442 |
| Jeffrey B. Kindler Executive Chairman, Director | Mar 10, 2018 | Option exercise | +11,667 | – | – | 11,667 |
| Ronald O. Perelman 10% owner | Dec 26, 2017 | Buy | +50,000 | $4.03 | $201.50K | 2,615,666 |
| Paul G. Savas Director | Dec 7, 2017 | Buy | +5,000 | $4.57 | $22.85K | 86,781 |
| Paul G. Savas Director | Dec 6, 2017 | Buy | +10,000 | $4.55 | $45.50K | 81,781 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Tuch Steven Officer | May 1, 2025 | 1,258 | $25.16K | May 1, 2025 | Exercised Shares |
| Tuch Steven Officer | Apr 29, 2025 | 1,000 | $21.50K | Apr 29, 2025 | Exercised Shares |
| Tuch Steven Officer | Apr 24, 2025 | 1,000 | $21.50K | Apr 24, 2025 | Exercised Shares |